Dr Alex Alderton
Head of Cellular Operations
Alex is the Head of Cellular Operations at the Wellcome Sanger Institute. In this role she leads a team of 55 scientists covering a broad range of scientific areas including flow cytometry, CRISPR genome editing, stem cells, high content imaging and organoid derivation. Collectively, the team provide cell biology expertise to help deliver some of the institutes largest and most ambitious projects.
Alex has a background in cell and molecular biology, in particular the development of cell lines and assays for large scale or high throughput science. She completed a Post doc on prion-based neurological disorders at the University of Bath in 2006 before joining Pfizer to work in cell line and assay development for a variety of early stage drug discovery projects. In 2012, Alex move to the Sanger to take up a senior role in the newly formed Cellular Generation and Phenotyping (CGaP) core facility, where she went onto become the facility head in 2015. In 2017, Alex moved into her current role as Head of Cellular Operations.
Head of Cellular Operations at the Sanger Institute
Head of Cellular Generation and Phenotyping at the Sanger Institute
Senior Scientific Manager at the Sanger Institute
Principal Scientist, Research Enabling Group at Pfizer
Senior Scientist, Primary Pharmacology Group at Pfizer
Screening Scientist, Primary Pharmacology Group at Pfizer
Post Doc at University of Bath
PhD in Molecular Biology, University of Kent
Programmes and Facilities
The Human Genetics Programme is driving a step-change in our understanding of genetic causes and biological mechanisms of disease susceptibility ...
We are focused on using single-cell approaches, so called “cell atlas” technologies and understanding human genetics at the cellular level. The ...
We develop and enhance high-throughput tools and technologies for malaria research to enable us to understand specific biological problems relevant for ...